Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 lenvatinib monotherapy for anaplastic thyroid cancer
2015-001929-17Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in anaplastic thyroid cancer (ATC), sponsored by Eisai Co., Ltd. Primary endpoint: Objective response rate by investigator (RECIST 1.1). Started Apr 2018; status: terminated.
02
Drugs
lenvatinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on 2015-001929-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001929-17.